Rhokiinsa

RSS

netarsudil

Authorised
This medicine is authorised for use in the European Union.

Overview

Rhokiinsa is an eye-drop solution that is used to reduce pressure inside the eye in adults who have open-angle glaucoma (a disease where the pressure in the eye rises because fluid cannot drain out of the eye) or ocular hypertension (when the pressure in the eye is higher than normal).

Rhokiinsa contains the active substance netarsudil.

This EPAR was last updated on 03/12/2019

Authorisation details

Product details
Name
Rhokiinsa
Agency product number
EMEA/H/C/004583
Active substance
Netarsudil
International non-proprietary name (INN) or common name
netarsudil
Therapeutic area (MeSH)
  • Glaucoma, Open-Angle
  • Ocular Hypertension
Anatomical therapeutic chemical (ATC) code
S01EX05
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Aerie Pharmaceuticals Ireland Ltd
Date of issue of marketing authorisation valid throughout the European Union
19/11/2019
Contact address

Aerie Pharmaceuticals Ireland Ltd
c/o William Fry Solicitors 6th Floor 2
Grand Canal Square
Dublin 2
D02 A342
Ireland

Product information

19/11/2019 Rhokiinsa - EMEA/H/C/004583 -

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Ophthalmologicals

Therapeutic indication

Reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension.

Assessment history

How useful was this page?

Add your rating